The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is a huge mover today! About 430,194 shares traded hands. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has risen 24.16% since March 15, 2016 and is uptrending. It has outperformed by 18.67% the S&P500.
The move comes after 6 months positive chart setup for the $3.81 billion company. It was reported on Oct, 18 by Barchart.com. We have $71.12 PT which if reached, will make NASDAQ:NBIX worth $2.36 billion more.
Analysts await Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to report earnings on November, 3. They expect $-0.57 EPS, down 42.50% or $0.17 from last year’s $-0.4 per share. After $-0.46 actual EPS reported by Neurocrine Biosciences, Inc. for the previous quarter, Wall Street now forecasts 23.91% negative EPS growth.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Ratings Coverage
Out of 6 analysts covering Neurocrine Biosci (NASDAQ:NBIX), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Neurocrine Biosci has been the topic of 6 analyst reports since August 18, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Tuesday, October 18 by Needham. The company was initiated on Thursday, April 7 by BMO Capital Markets. The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has “Outperform” rating given on Monday, October 12 by Leerink Swann. The rating was maintained by Piper Jaffray with “Overweight” on Thursday, October 8. As per Wednesday, June 29, the company rating was initiated by H.C. Wainwright. The rating was reinitiated by Jefferies with “Buy” on Tuesday, August 18.
According to Zacks Investment Research, “Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company’s neuroscience, endocrine and immunology disciplines provide a unique biological understanding of the molecular interaction between central nervous, immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity and diabetes.”
Insitutional Activity: The institutional sentiment decreased to 0.89 in Q2 2016. Its down 0.21, from 1.1 in 2016Q1. The ratio is negative, as 18 funds sold all Neurocrine Biosciences, Inc. shares owned while 89 reduced positions. 37 funds bought stakes while 58 increased positions. They now own 83.14 million shares or 3.77% less from 86.40 million shares in 2016Q1.
Fred Alger Mngmt holds 0.01% or 38,120 shares in its portfolio. Mutual Of America Capital Mngmt Llc holds 0.07% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 71,904 shares. Creative Planning has 5,300 shares for 0% of their US portfolio. Cap Fund Mgmt Sa holds 0.03% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 77,121 shares. California State Teachers Retirement Sys last reported 181,851 shares in the company. Legal And General Grp Inc Public Limited owns 6,999 shares or 0% of their US portfolio. Meeder Asset Mngmt reported 154 shares or 0% of all its holdings. Us Financial Bank De holds 0% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 528 shares. Highbridge Cap Mngmt Ltd Liability holds 0.01% or 8,762 shares in its portfolio. Aperio Group Incorporated Ltd Limited Liability Company has 11,520 shares for 0% of their US portfolio. Pnc Finance Gru Inc last reported 0% of its portfolio in the stock. Stephens Ar owns 4,500 shares or 0.01% of their US portfolio. Rock Springs Cap Mngmt Limited Partnership has 1.38% invested in the company for 409,500 shares. Moreover, Diam has 0.12% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 170,367 shares. National Bank & Trust Of Montreal Can holds 720 shares or 0% of its portfolio.
Insider Transactions: Since May 16, 2016, the stock had 0 buys, and 7 insider sales for $4.20 million net activity. Shares for $625,000 were sold by OBrien Christopher Flint. 9,000 shares with value of $450,000 were sold by Lloyd-Smith Malcolm on Thursday, September 1. 5,000 shares were sold by Nevinny Corinne H, worth $242,700 on Monday, August 8. POPS RICHARD F sold 15,000 shares worth $700,800.
More notable recent Neurocrine Biosciences, Inc. (NASDAQ:NBIX) news were published by: Prnewswire.com which released: “Neurocrine Biosciences to Present at the Baird 2016 Healthcare Conference” on August 31, 2016, also Prnewswire.com with their article: “Neurocrine Announces INGREZZAâ„¢ (valbenazine) New Drug Application for the …” published on October 11, 2016, Fool.com published: “Why Neurocrine Biosciences Inc.’s Stock Skyrocketed 147% Higher in 2015” on January 14, 2016. More interesting news about Neurocrine Biosciences, Inc. (NASDAQ:NBIX) were released by: Prnewswire.com and their article: “Neurocrine Biosciences to Present at the Morgan Stanley Global Healthcare …” published on August 31, 2016 as well as Prnewswire.com‘s news article titled: “Neurocrine Submits New Drug Application for Valbenazine for Treatment of …” with publication date: August 29, 2016.
NBIX Company Profile
Neurocrine Biosciences, Inc., incorporated on March 20, 1996, is engaged in the development of pharmaceutical products focused on neurological and endocrine diseases and disorders. The Company’s two lead late-stage clinical programs are Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc. (AbbVie), and NBI-98854 (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. The Firm focuses on developing NBI-640756 against Essential tremor. The Company’s research and development focuses on addressing diseases and disorders of the central nervous and endocrine systems, which include therapeutic categories ranging from hypothalamic-pituitary-adrenal (HPA) disorders to stress-related disorders and neurological/neuropsychiatric diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.